Top

Current Hepatology Reports

Published in:

01-09-2018 | Drug-Induced Liver Injury (NP Chalasani and MS Ghabril, Section Editors)

Drug-Induced Liver Injury in Children

Authors: Frank DiPaola, Jean P. Molleston

Published in: Current Hepatology Reports | Issue 3/2018

Abstract

Purpose of Review

Drug-induced liver injury (DILI) is relatively rare among children but can cause substantial morbidity and mortality. Here, we summarize the literature on pediatric DILI including a focus on commonly used classes of drugs.

Recent Findings

The incidence of pediatric DILI remains poorly defined. Antimicrobials and antiepileptic medications are the most commonly reported causes of pediatric idiosyncratic DILI in the US DILI network (DILIN) experience. DILI among children being treated for cancer appears to be underreported, and recent literature clearly implicates newer classes of agents such as tumor necrosis factor-α inhibitors as potentially hepatotoxic. Many drugs trigger signature patterns of DILI; autoimmune hepatitis secondary to minocycline is an example.

Summary

DILI should be suspected whenever a child presents with evidence of liver injury. Familiarity with established patterns of DILI secondary to specific agents can facilitate recognition of cases. Active reporting of cases by clinicians to registries such as US DILIN remains critical to a continuing understanding of the causes and risk factors of DILI among children.

Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296(15):1858–66. https://doi.org/10.1001/jama.296.15.1858.CrossRefPubMed

Budnitz DS, Salis S. Preventing medication overdoses in young children: an opportunity for harm elimination. Pediatrics. 2011;127(6):e1597–9. https://doi.org/10.1542/peds.2011-0926.CrossRefPubMed

Regev A. How to avoid being surprised by hepatotoxicity at the final stages of drug development and approval. Clin Liver Dis. 2013;17(4):749–67, xi. https://doi.org/10.1016/j.cld.2013.07.014.CrossRefPubMed

Lee WM. Drug-induced acute liver failure. Clin Liver Dis. 2013;17(4):575–86. https://doi.org/10.1016/j.cld.2013.07.001. viiiCrossRefPubMed

•• Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(7):1340–52 e7. https://doi.org/10.1053/j.gastro.2015.03.006. Most recent review of data from the US Drug-Induced Liver Injury Network prospective study. CrossRefPubMedPubMedCentral

• Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451–5. https://doi.org/10.1053/jhep.2002.34857. Population-based study of DILI from France. CrossRefPubMed

• Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–25, 25 e1–3; quiz e19–20. https://doi.org/10.1053/j.gastro.2013.02.006. Population-based study of DILI from Iceland. CrossRef

CDC. Health, United States, 2016. https://www.cdc.gov/nchs/hus/contents2016.htm#079. Accessed July 31st, 2017 2017.

Alonso RHSaEM. Acute liver failure in children. In: Frederick Suchy, Ronald Sokol, William Balistreri, editor. Liver disease in children. 4 ed.: Cambridge University Press; 2014.

10.

Saneto RP, Lee IC, Koenig MK, Bao X, Weng SW, Naviaux RK, et al. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure. 2010;19(3):140–6. https://doi.org/10.1016/j.seizure.2010.01.002.CrossRefPubMedPubMedCentral

11.

Star K, Edwards IR, Choonara I. Valproic acid and fatalities in children: a review of individual case safety reports in VigiBase. PLoS One. 2014;9(10):e108970. https://doi.org/10.1371/journal.pone.0108970.CrossRefPubMedPubMedCentral

12.

•• LiverTox. https://livertox.nlm.nih.gov//. LiverTox is an online, searchable database providing up-to-date information on the characteristics of DILI related to prescription and nonprescription medications, herbals, and dietary supplements.

13.

Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51(6):2117–26. https://doi.org/10.1002/hep.23577.CrossRefPubMedPubMedCentral

14.

Colantonio DA, Kyriakopoulou L, Chan MK, Daly CH, Brinc D, Venner AA, et al. Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children. Clin Chem. 2012;58(5):854–68. https://doi.org/10.1373/clinchem.2011.177741.CrossRefPubMed

15.

Adeli K, Higgins V, Nieuwesteeg M, Raizman JE, Chen Y, Wong SL, et al. Complex reference values for endocrine and special chemistry biomarkers across pediatric, adult, and geriatric ages: establishment of robust pediatric and adult reference intervals on the basis of the Canadian Health Measures Survey. Clin Chem. 2015;61(8):1063–74. https://doi.org/10.1373/clinchem.2015.240523.CrossRefPubMed

16.

• Molleston JP, Fontana RJ, Lopez MJ, Kleiner DE, Gu J, Chalasani N, et al. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr. 2011;53(2):182–9. https://doi.org/10.1097/MPG.0b013e31821d6cfd. The initial review of pediatric data from the US Drug-Induced Liver Injury Network prospective study. CrossRefPubMedPubMedCentral

17.

DiPaola F, Molleston JP, Gu S, Cirulli ET, Chalasani N, Barnhart H, et al. Minocycline and anti-epileptics are the leading causes of DILI in children: a report from the US Drug-Induced Liver Injury Network. Washington, DC: The Liver Meeting, American Association for the Study of Liver diseases; 2017.

18.

Hicks LA, Bartoces MG, Roberts RM, Suda KJ, Hunkler RJ, Taylor TH Jr, et al. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. Clin Infect Dis. 2015;60(9):1308–16. https://doi.org/10.1093/cid/civ076. CrossRefPubMed

19.

Olson SC, Smith S, Weissman SJ, Kronman MP. Adverse events in pediatric patients receiving long-term outpatient antimicrobials. J Pediatric Infect Dis Soc. 2015;4(2):119–25. https://doi.org/10.1093/jpids/piu037.CrossRefPubMed

20.

Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56(4):958–76. https://doi.org/10.1007/s10620-011-1611-4.CrossRefPubMed

21.

Kumar A, Sood V, Khanna R, Verma SK, Mehra N, Rawat D, et al. Clinical spectrum and outcome of pediatric drug induced liver injury. Indian J Pediatr. 2017; https://doi.org/10.1007/s12098-017-2570-3.CrossRef

22.

Devarbhavi H, Patil M, Reddy VV, Singh R, Joseph T, Ganga D. Drug-induced acute liver failure in children and adults: results of a single-centre study of 128 patients. Liver Int. 2017;38:1322–9. https://doi.org/10.1111/liv.13662. CrossRefPubMed

23.

Yang LX, Liu CY, Zhang LL, Lai LL, Fang M, Zhang C. Clinical characteristics of patients with drug-induced liver injury. Chin Med J. 2017;130(2):160–4. https://doi.org/10.4103/0366-6999.197995. CrossRefPubMedPubMedCentral

24.

Zhu Y, Li YG, Wang JB, Liu SH, Wang LF, Zhao YL, et al. Causes, features, and outcomes of drug-induced liver injury in 69 children from China. Gut Liver. 2015;9(4):525–33. https://doi.org/10.5009/gnl14184.CrossRefPubMedPubMedCentral

25.

Chang SH, Nahid P, Eitzman SR. Hepatotoxicity in children receiving isoniazid therapy for latent tuberculosis infection. J Pediatric Infect Dis Soc. 2014;3(3):221–7. https://doi.org/10.1093/jpids/pit089.CrossRefPubMed

26.

Hayashi PH, Fontana RJ, Chalasani NP, Stolz AA, Talwalkar JA, Navarro VJ, et al. Under-reporting and poor adherence to monitoring guidelines for severe cases of isoniazid hepatotoxicity. Clin Gastroenterol Hepatol. 2015;13(9):1676–82 e1. https://doi.org/10.1016/j.cgh.2015.02.024.CrossRefPubMedPubMedCentral

27.

Martinez MA, Vuppalanchi R, Fontana RJ, Stolz A, Kleiner DE, Hayashi PH, et al. Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol. 2015;13(2):369–76.e3. https://doi.org/10.1016/j.cgh.2014.07.054.CrossRefPubMed

28.

Karthik SV, Casson D. Erythromycin-associated cholestatic hepatitis and liver dysfunction in children: the British experience. J Clin Gastroenterol. 2005;39(8):743–4.CrossRef

29.

Zafrani ES, Ishak KG, Rudzki C. Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases. Dig Dis Sci. 1979;24(5):385–96.CrossRef

30.

Ginsburg CM. A prospective study on the incidence of liver function abnormalities in children receiving erythromycin estolate, erythromycin ethylsuccinate or penicillin V for treatment of pneumonia. Pediatr Infect Dis. 1986;5(1):151–3.CrossRef

31.

Maraqa NF, Gomez MM, Rathore MH, Alvarez AM. Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials. Clin Infect Dis. 2002;34(1):50–4. https://doi.org/10.1086/338047. CrossRefPubMed

32.

Olans RN, Weiner LB. Reversible oxacillin hepatotoxicity. J Pediatr. 1976;89(5):835–8.CrossRef

33.

• Chalasani N, Reddy KRK, Fontana RJ, Barnhart H, Gu J, Hayashi PH, et al. Idiosyncratic drug induced liver injury in African-Americans is associated with greater morbidity and mortality compared to Caucasians. Am J Gastroenterol. 2017;112(9):1382–8. https://doi.org/10.1038/ajg.2017.215. Analysis from US DILIN demonstrating key differences in etiologies and outcomes of DILI by race. CrossRefPubMedPubMedCentral

34.

Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH, et al. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. Br J Clin Pharmacol. 2010;70(5):721–8. https://doi.org/10.1111/j.1365-2125.2010.03754.x.CrossRefPubMedPubMedCentral

35.

Stewart JD, Horvath R, Baruffini E, Ferrero I, Bulst S, Watkins PB, et al. Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology. 2010;52(5):1791–6. https://doi.org/10.1002/hep.23891.CrossRefPubMed

36.

Li S, Guo J, Ying Z, Chen S, Yang L, Chen K, et al. Valproic acid-induced hepatotoxicity in Alpers syndrome is associated with mitochondrial permeability transition pore opening-dependent apoptotic sensitivity in an induced pluripotent stem cell model. Hepatology. 2015;61(5):1730–9. https://doi.org/10.1002/hep.27712.CrossRefPubMed

37.

Brown TS, Appel JE, Kasteler JS, Callen JP. Hypersensitivity reaction in a child due to lamotrigine. Pediatr Dermatol. 1999;16(1):46–9.CrossRef

38.

Bhayana H, Appasani S, Thapa BR, Das A, Singh K. Lamotrigine-induced vanishing bile duct syndrome in a child. J Pediatr Gastroenterol Nutr. 2012;55(6):e147–8. https://doi.org/10.1097/MPG.0b013e31823c2500.CrossRefPubMed

39.

Matsukura H, Suzuki Y. A case of hepatitis associated with carbamazepine therapy. Eur J Pediatr. 1988;147(6):666.CrossRef

40.

Hadzic N, Portmann B, Davies ET, Mowat AP, Mieli-Vergani G. Acute liver failure induced by carbamazepine. Arch Dis Child. 1990;65(3):315–7.CrossRef

41.

Horneff G, Lenard HG, Wahn V. Severe adverse reaction to carbamazepine: significance of humoral and cellular reactions to the drug. Neuropediatrics. 1992;23(5):272–5. https://doi.org/10.1055/s-2008-1071357.CrossRefPubMed

42.

Bellman B, Schachner LA, Pravder L, McFalls S, Shapiro B. Carbamazepine hypersensitivity. J Am Acad Child Adolesc Psychiatry. 1995;34(11):1405–6. https://doi.org/10.1097/00004583-199511000-00005.CrossRefPubMed

43.

Troost RJ, Oranje AP, Lijnen RL, Benner R, Prens EP. Exfoliative dermatitis due to immunologically confirmed carbamazepine hypersensitivity. Pediatr Dermatol. 1996;13(4):316–20.CrossRef

44.

Wadhawan M, Tyagi P, Malhotra V, Sakhuja P, Puri AS. Reversible cholestatic hepatitis due to carbamazepine in an adolescent. Indian J Gastroenterol. 2005;24(4):172–3.PubMed

45.

Aouam K, Ben Romdhane F, Loussaief C, Salem R, Toumi A, Belhadjali H, et al. Hypersensitivity syndrome induced by anticonvulsants: possible cross-reactivity between carbamazepine and lamotrigine. J Clin Pharmacol. 2009;49(12):1488–91. https://doi.org/10.1177/0091270009344985.CrossRefPubMed

46.

Devarbhavi H, Karanth D, Prasanna KS, Adarsh CK, Patil M. Drug-induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents. Hepatology. 2011;54(4):1344–50. https://doi.org/10.1002/hep.24527.CrossRefPubMed

47.

Buyuktiryaki AB, Bezirganoglu H, Sahiner UM, Yavuz ST, Tuncer A, Kara A, et al. Patch testing is an effective method for the diagnosis of carbamazepine-induced drug reaction, eosinophilia and systemic symptoms (DRESS) syndrome in an 8-year-old girl. Aust J Dermatol. 2012;53(4):274–7. https://doi.org/10.1111/j.1440-0960.2012.00887.x.CrossRef

48.

Teng P, Tan B. Carbamazepine-induced DRESS syndrome in a child: rapid response to pulsed corticosteroids. Dermatol Online J. 2013;19(5):18170.PubMed

49.

Arnon R, DeVivo D, Defelice AR, Kazlow PG. Acute hepatic failure in a child treated with lamotrigine. Pediatr Neurol. 1998;18(3):251–2.CrossRef

50.

Zucker P, Daum F, Cohen MI. Fatal carbamazepine hepatitis. J Pediatr. 1977;91(4):667–8.CrossRef

51.

Luke DR, Rocci ML Jr, Schaible DH, Ferguson RK. Acute hepatotoxicity after excessively high doses of carbamazepine on two occasions. Pharmacotherapy. 1986;6(3):108–11.CrossRef

52.

Viani F, Claris-Appiani A, Rossi LN, Giani M, Romeo A. Severe hepatorenal failure in a child receiving carbamazepine and erythromycin. Eur J Pediatr. 1992;151(9):715.CrossRef

53.

Haase MR. Carbamazepine-induced hepatorenal failure in a child. Pharmacotherapy. 1999;19(5):667–71.CrossRef

54.

Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm. 2004;61(22):2391–9.PubMed

55.

Lim JR, Faught PR, Chalasani NP, Molleston JP. Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr. 2006;148(6):831–4. https://doi.org/10.1016/j.jpeds.2006.01.035.CrossRefPubMed

56.

Stojanovski SD, Casavant MJ, Mousa HM, Baker P, Nahata MC. Atomoxetine-induced hepatitis in a child. Clin Toxicol (Phila). 2007;45(1):51–5.CrossRef

57.

Erdogan A, Ozcay F, Piskin E, Karaman MG, Bilezikci B, Calik M, et al. Idiosyncratic liver failure probably associated with atomoxetine: a case report. J Child Adolesc Psychopharmacol. 2011;21(3):295–7. https://doi.org/10.1089/cap.2010.0101.CrossRefPubMed

58.

Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol. 2006;33(1):50–67. https://doi.org/10.1053/j.seminoncol.2005.11.002.CrossRefPubMed

59.

McDonald GB, Frieze D. A problem-oriented approach to liver disease in oncology patients. Gut. 2008;57(7):987–1003. https://doi.org/10.1136/gut.2007.131136.CrossRefPubMed

60.

Castellino S, Muir A, Shah A, Shope S, McMullen K, Ruble K, et al. Hepato-biliary late effects in survivors of childhood and adolescent cancer: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2010;54(5):663–9. https://doi.org/10.1002/pbc.22265. CrossRefPubMedPubMedCentral

61.

Ebbesen MS, Nygaard U, Rosthoj S, Sorensen D, Nersting J, Vettenranta K, et al. Hepatotoxicity during maintenance therapy and prognosis in children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2017;39(3):161–6. https://doi.org/10.1097/mph.0000000000000733.CrossRefPubMed

62.

Raetz EA, Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;32(7):554–63. https://doi.org/10.1097/MPH.0b013e3181e6f003.CrossRefPubMed

63.

Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52(12):2237–53. https://doi.org/10.3109/10428194.2011.596963.CrossRefPubMed

64.

Hijiya N, van der Sluis IM. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2016;57(4):748–57. https://doi.org/10.3109/10428194.2015.1101098.CrossRefPubMed

65.

Ricart AD. Drug-induced liver injury in Oncology. Ann Oncol. 2017;28(8):2013–20. https://doi.org/10.1093/annonc/mdx158.CrossRefPubMed

66.

Stoneham S, Lennard L, Coen P, Lilleyman J, Saha V. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. Br J Haematol. 2003;123(1):100–2.CrossRef

67.

Al-Mukhaizeem KA, Rosenberg A, Sherker AH. Nodular regenerative hyperplasia of the liver: an under-recognized cause of portal hypertension in hematological disorders. Am J Hematol. 2004;75(4):225–30. https://doi.org/10.1002/ajh.20024.CrossRefPubMed

68.

Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology. 2006;44(1):7–14. https://doi.org/10.1002/hep.21258.CrossRefPubMed

69.

Gisbert JP, Gonzalez-Lama Y, Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2007;102(7):1518–27. https://doi.org/10.1111/j.1572-0241.2007.01187.x.CrossRefPubMed

70.

Bastida G, Nos P, Aguas M, Beltran B, Rubin A, Dasi F, et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;22(9):775–82. https://doi.org/10.1111/j.1365-2036.2005.02636.x.CrossRefPubMed

71.

Gisbert JP, Luna M, Gonzalez-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis. 2007;13(9):1106–14. https://doi.org/10.1002/ibd.20160.CrossRefPubMed

72.

Moran GW, Dubeau MF, Kaplan GG, Yang H, Eksteen B, Ghosh S, et al. Clinical predictors of thiopurine-related adverse events in Crohn’s disease. World J Gastroenterol. 2015;21(25):7795–804. https://doi.org/10.3748/wjg.v21.i25.7795.CrossRefPubMedPubMedCentral

73.

Bjornsson ES, Gu J, Kleiner DE, Chalasani N, Hayashi PH, Hoofnagle JH, et al. Azathioprine and 6-mercaptopurine-induced liver injury: clinical features and outcomes. J Clin Gastroenterol. 2017;51(1):63–9. https://doi.org/10.1097/MCG.0000000000000568.CrossRefPubMedPubMedCentral

74.

Kuriyama M, Kato J, Suzuki H, Akita M, Hiraoka S, Okada H, et al. Tolerability and usefulness of mercaptopurine in azathioprine-intolerant Japanese patients with ulcerative colitis. Dig Endosc. 2010;22(4):289–96. https://doi.org/10.1111/j.1443-1661.2010.01009.x.CrossRefPubMed

75.

Knowles SR, Gupta AK, Shear NH, Sauder D. Azathioprine hypersensitivity-like reactions—a case report and a review of the literature. Clin Exp Dermatol. 1995;20(4):353–6.CrossRef

76.

Herfarth HH, Kappelman MD, Long MD, Isaacs KL. Use of methotrexate in the treatment of inflammatory bowel diseases. Inflamm Bowel Dis. 2016;22(1):224–33. https://doi.org/10.1097/MIB.0000000000000589. CrossRefPubMedPubMedCentral

77.

Turner D, Grossman AB, Rosh J, Kugathasan S, Gilman AR, Baldassano R, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn’s disease. Am J Gastroenterol. 2007;102(12):2804–12. https://doi.org/10.1111/j.1572-0241.2007.01474.x. quiz 3, 13CrossRefPubMed

78.

Haisma SM, Lijftogt T, Kindermann A, Damen G, de Ridder L, Escher JC, et al. Methotrexate for maintaining remission in paediatric Crohn’s patients with prior failure or intolerance to thiopurines: a multicenter cohort study. J Crohns Colitis. 2015;9(4):305–11. https://doi.org/10.1093/ecco-jcc/jjv031.CrossRefPubMed

79.

Sunseri W, Hyams JS, Lerer T, Mack DR, Griffiths AM, Otley AR, et al. Retrospective cohort study of methotrexate use in the treatment of pediatric Crohn’s disease. Inflamm Bowel Dis. 2014;20(8):1341–5. https://doi.org/10.1097/MIB.0000000000000102.CrossRefPubMed

80.

Turner D, Doveh E, Cohen A, Wilson ML, Grossman AB, Rosh JR, et al. Efficacy of oral methotrexate in paediatric Crohn’s disease: a multicentre propensity score study. Gut. 2015;64(12):1898–904. https://doi.org/10.1136/gutjnl-2014-307964.CrossRefPubMed

81.

Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, et al. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4(3):221–56. https://doi.org/10.1016/j.crohns.2009.12.001.CrossRefPubMed

82.

Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, et al. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11(5):558–64 e3. https://doi.org/10.1016/j.cgh.2012.12.025.CrossRefPubMed

83.

French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky HL. Hepatotoxicity associated with the use of anti-TNF-alpha agents. Drug Saf. 2016;39(3):199–208. https://doi.org/10.1007/s40264-015-0366-9.CrossRefPubMedPubMedCentral

84.

Mostamand S, Schroeder S, Schenkein J, Miloh T. Infliximab-associated immunomediated hepatitis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2016;63(1):94–7. https://doi.org/10.1097/MPG.0000000000001137.CrossRefPubMed

85.

Ricciuto A, Kamath BM, Walters TD, Frost K, Carman N, Church PC, et al. New onset autoimmune hepatitis during anti-tumor necrosis factor-alpha treatment in children. J Pediatr. 2018;194:128–35 e1. https://doi.org/10.1016/j.jpeds.2017.10.071.CrossRefPubMed

86.

Seeff LB, Bonkovsky HL, Navarro VJ, Wang G. Herbal products and the liver: a review of adverse effects and mechanisms. Gastroenterology. 2015;148(3):517–32.e3. https://doi.org/10.1053/j.gastro.2014.12.004.CrossRefPubMed

87.

Lawrenson JA, Walls T, Day AS. Echinacea-induced acute liver failure in a child. J Paediatr Child Health. 2014;50(10):841. https://doi.org/10.1111/jpc.12726.CrossRefPubMed

88.

• Navarro VJ, Khan I, Bjornsson E, Seeff LB, Serrano J, Hoofnagle JH. Liver injury from herbal and dietary supplements. Hepatology. 2017;65(1):363–73. https://doi.org/10.1002/hep.28813. Review of etiology and diagnosis of herbal and supplement DILI that emphasizes the need to clarify purity and safety. CrossRefPubMed

Title: Drug-Induced Liver Injury in Children
Authors: Frank DiPaola
Jean P. Molleston
Publication date: 01-09-2018
Publisher: Springer US
Published in: Current Hepatology Reports / Issue 3/2018
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-018-0413-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2018

Drug-Induced Liver Injury: Understanding the Different Immune-Mediated Phenotypes and Clinical Management

Is Exercise Beneficial and Safe in Patients with Cirrhosis and Portal Hypertension?

Treatment of Gastro-Fundal Varices (Including a Discussion of BRTO)

Beware of HCV and HEV in Patients with Suspected Drug-Induced Liver Injury

The Role of Anticoagulation in Treating Portal Hypertension

Drug-Induced Fatty Liver Disease

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage